Clindamycin

Detailed information

Comment on Fass environmental information

Clindamycin has different classifications on fass.se. According to Lif (the trade association for the research-based pharmaceutical industry in Sweden) the various pharmaceutical companies compile environmental information for their active substances based on internal studies and published data. Based on data, which may thus differ between different pharmaceutical companies, the companies assess the environmental risk with guidance from “Environmental classification of pharmaceuticals at www.fass.se – Guidance for pharmaceutical companies 2012”. The Swedish Environmental Institute (IVL) reviews the assessment but does not have the task of coordinating/harmonizing environmental information from different pharmaceutical companies for the same active substance. It is also voluntary for manufacturers to provide information on the environmental impact on fass.se.

Fass environmental information for Duac

Fass environmental information for Duac (clindamycin, benzoyl peroxide) from GSK (downloaded 2022-11-16).

Hazard

Persistence: No data.

Bioaccumulation: "Log Dow_calc at pH 7 = 0.38. Since log Kow < 4 at pH 7, the substance has a low potential for bioaccumulation."

Toxicity: No data.

Risk

Risk of environmental impact of clindamycin cannot be excluded, due to the lack of environmental toxicity data.

Fass environmental information for Dalacin

Fass environmental information for Dalacin (clindamycin) from Pfizer (downloaded 2022-11-16).

Hazard

Persistence: No data.

Bioaccumulation: No data.

Toxicity: No data.

Risk

Risk of environmental impact of clindamycin cannot be excluded, due to the lack of environmental toxicity data.

EU water legislation

"During 2021, the Commission gathered data on a range of other substances that could be included in the watch list. It took into account the different types of relevant information referred to in Article 8b(1) of Directive 2008/105/EC, and consulted experts from Member States and stakeholder groups. Substances for which doubt exists about their toxicity, or for which the sensitivity, reliability or comparability of the available monitoring methods are not adequate, should not be included in the watch list. The fungicide azoxystrobin, the herbicide diflufenican, the insecticide and veterinary pharmaceutical fipronil, the antibiotics clindamycin and ofloxacin, the human pharmaceutical metformin and its metabolite guanylurea, and a group of three sunscreen agents (butyl methoxydibenzoylmethane, also known as avobenzone; octocrylene; and benzophenone-3, also known as oxybenzone) were identified as suitable candidates. The addition of the pharmaceuticals is consistent with the EU Strategic Approach to Pharmaceuticals in the Environment (6), and the inclusion of the two antibiotics is also consistent with the European One Health Action Plan against Antimicrobial Resistance (AMR) (7), which supports the use of the watch list to ‘improve knowledge of the occurrence and spread of antimicrobials in the environment’."